<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="363376">
  <stage>Registered</stage>
  <submitdate>12/12/2012</submitdate>
  <approvaldate>9/01/2013</approvaldate>
  <actrnumber>ACTRN12613000026729</actrnumber>
  <trial_identification>
    <studytitle>An investigation of the effects of intranasal oxytocin on socio-emotional brain regions in Huntingtons disease</studytitle>
    <scientifictitle>An investigation of the effects of intranasal oxytocin on socio-emotional brain regions in Huntingtons disease</scientifictitle>
    <utrn>U1111-1137-8675</utrn>
    <trialacronym />
    <secondaryid>None</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Huntington's disease</healthcondition>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Neurodegenerative diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Mental Health</conditioncode1>
      <conditioncode2>Other mental health disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Human Genetics and Inherited Disorders</conditioncode1>
      <conditioncode2>Other human genetics and inherited disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Two acute (24 IU) treatment conditions including; a) intranasal placebo, and b) intranasal oxytocin (Syntocinon, Novartis, Switzerland). The two treatment conditions will be separated by a minimum of 1 week (washout period). The nasal sprays will be administered 50 mins prior to the functional magnetic resonance (fMR) protocol. The fMRI protocol will involve showing participants a brief task involving pictures of human faces expressing different emotions.  </interventions>
    <comparator>Placebo, a saline solution without the active (peptide) ingredient.
Healthy controls will as be used in comparisons to the HD patients.</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Functional MRI (fMRI) data will be collected in response to an emotional face expression task. The fMRI data will be compared within the patient (Huntington's disease) group for differences in brain response (e.g., in the amygdala) between placebo and oxytocin conditions. </outcome>
      <timepoint>The data will be collected in the 50-80 min post drug administration and will be analysed post all data collection.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Using the fMRI data, the patients with Huntington's disease will be compared to controls on brain response (e.g., amygdala) under normal (placebo) conditions to see whether hyper- or hypo-activity is present.</outcome>
      <timepoint>The data will be collected in the 50-80 min post drug administration and will be analysed post all data collection.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>For Healthy controls: Males; Right-handed; between the ages of 25-55 years; non-smoker and no drug/alcohol abuse; medication free; and no metal objects present in body (or which can't be removed or which is not MRI safe). 
For Huntington's disease (HD): As above plus a diagnosis of the disease is required.</inclusivecriteria>
    <inclusiveminage>25</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>55</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Males</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Clinically significant medical or neurological condition (other than HD for the patients), significant head injury (or loss of consciousness from longer than 5 mins), presence of ferrous-containing metals within the body, inability to tolerate small enclosed spaces without anxiety.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>False</masking1>
    <masking2>False</masking2>
    <masking3>False</masking3>
    <masking4>False</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>20/11/2012</anticipatedstartdate>
    <actualstartdate>20/11/2012</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>40</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>Monash Biomedical Imaging</primarysponsorname>
    <primarysponsoraddress>Building 220, 770 Wellington rd, Clayton, VIC, 3800</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>Monash Biomedical Imaging Psych Grant</fundingname>
      <fundingaddress>Building 220, 770 Wellington rd, Clayton, VIC, 3800</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The overall aim of the current study is to examine the brain correlates of emotion recognition in patients with HD using a double-blind placebo controlled intranasal oxytocin design and two MRI techniques involving fMRI and diffusion tensor imaging (DTI).</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Monash University Human Research Ethics Committee (MUHREC)</ethicname>
      <ethicaddress>Building 3E, Room 111, Clayton Campus, Wellington Rd, Clayton, VIC, 3800.</ethicaddress>
      <ethicapprovaldate>25/09/2012</ethicapprovaldate>
      <hrec>CF12/2082 - 2012001135</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Izelle Labuschagne</name>
      <address>Building 17, Wellington Rd, School of Psychology and Psychiatry, Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton Campus, VIC, 3800.</address>
      <phone>61399020481</phone>
      <fax />
      <email>izelle.labuschagne@monash.edu</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Izelle Labuschagne</name>
      <address>Building 17, Wellington Rd, School of Psychology and Psychiatry, Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton Campus, VIC, 3800.</address>
      <phone>61399020481</phone>
      <fax />
      <email>izelle.labuschagne@monash.edu</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Izelle Labuschagne</name>
      <address>Building 17, Wellington Rd, School of Psychology and Psychiatry, Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton Campus, VIC, 3800.</address>
      <phone>61399020481</phone>
      <fax />
      <email>izelle.labuschagne@monash.edu</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Izelle Labuschagne</name>
      <address>Building 17, School of Psychology and Psychiatry, Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton Campus, VIC, 3800.</address>
      <phone>61399020481</phone>
      <fax />
      <email>izelle.labuschagne@monash.edu</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>